{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:25:46Z","timestamp":1786991146799,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007475","name":"Canadian Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007475","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jaad.2018.07.004","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T22:15:40Z","timestamp":1531174540000},"page":"1089-1100.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"79","author":[{"given":"Pingxing","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lefran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2018.07.004_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archdermatol.2010.19","article-title":"Incidence estimate of nonmelanoma skin cancer in the United States, 2006","volume":"146","author":"Rogers","year":"2010","journal-title":"Arch Dermatol"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2018.07.004_bib2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0190-9622(08)81509-5","article-title":"Nonmelanoma skin cancer in the United States: incidence","volume":"30","author":"Miller","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.004_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2016.06.020","article-title":"Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (laBCC) in a large commercially insured population in the United States: a retrospective cohort study","volume":"75","author":"Goldenberg","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"10.1016\/j.jaad.2018.07.004_bib4","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.004_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1684\/ejd.2017.3031","article-title":"Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review","volume":"27","author":"Lear","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.004_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jamadermatol.2013.3064","article-title":"Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011","volume":"149","author":"Wysong","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.004_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2133.1992.tb08050.x","article-title":"Extensive and fatal basal cell carcinoma: a report of three cases","volume":"127","author":"Ko","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.07.004_bib8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJM196005052621803","article-title":"Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome","volume":"262","author":"Gorlin","year":"1960","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jaad.2018.07.004_bib9","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1074\/jbc.271.21.12125","article-title":"A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities","volume":"271","author":"Hahn","year":"1996","journal-title":"J Biol Chem"},{"issue":"5678","key":"10.1016\/j.jaad.2018.07.004_bib10","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1126\/science.1098020","article-title":"The hedgehog response network: sensors, switches, and routers","volume":"304","author":"Lum","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.004_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8020022","article-title":"Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors","volume":"8","author":"Rimkus","year":"2016","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.jaad.2018.07.004_bib12","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2018.07.004_bib13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1001\/jamadermatol.2016.0780","article-title":"Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies","volume":"152","author":"Jacobsen","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.004_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.004_bib15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-14-1234","article-title":"Phase I dose-escalation trial of the oral investigational hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors","volume":"21","author":"Goldman","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.004_bib16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","article-title":"Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma","volume":"32","author":"Kim","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2018.07.004_bib17","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.004_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"9","key":"10.1016\/j.jaad.2018.07.004_bib19","first-page":"956","article-title":"Vismodegib for locally advanced basal cell carcinoma: descriptive analysis of a case series and comparison to the literature","volume":"14","author":"Viscusi","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.004_bib20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jaad.2015.07.016","article-title":"Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp","volume":"73","author":"Tauber","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.004_bib21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","article-title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","volume":"16","author":"Basset-Seguin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.004_bib22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.004_bib23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","article-title":"Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome","volume":"160","author":"Ozgur","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.004_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2015.03.013","article-title":"A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma","volume":"73","author":"Sofen","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.004_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","article-title":"Efficacy of vismodegib (Erivedge) for basal cell carcinoma involving the orbit and periocular area","volume":"31","author":"Demirci","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.004_bib26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","article-title":"Expanded access study of patients with advanced basal cell carcinoma treated with the hedgehog pathway inhibitor, vismodegib","volume":"70","author":"Chang","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2018.07.004_bib27","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","article-title":"Vismodegib for periocular and orbital basal cell carcinoma","volume":"131","author":"Gill","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.004_bib28","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.004_bib29","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jaad.2015.12.035","article-title":"Four-year experience with vismodegib hedgehog inhibitor therapy","volume":"74","author":"Simone","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2018.07.004_bib32","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S1470-2045(16)30566-6","article-title":"Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Tang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.004_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2016.02.1226","article-title":"The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma","volume":"75","author":"Dummer","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.004_bib35","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1078-0432.CCR-15-1588","article-title":"An Investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib","volume":"22","author":"Danial","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.004_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ccell.2015.02.001","article-title":"Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma","volume":"27","author":"Sharpe","year":"2015","journal-title":"Cancer Cell"},{"issue":"9270","key":"10.1016\/j.jaad.2018.07.004_bib37","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(00)04891-1","article-title":"Congestive heart failure associated with itraconazole","volume":"357","author":"Ahmad","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaad.2018.07.004_bib38","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdv390","article-title":"Alopecia in patients treated with molecularly targeted anticancer therapies","volume":"26","author":"Belum","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.004_bib39","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/bjd.13630","article-title":"Persistent alopecia induced by vismodegib","volume":"172","author":"Alkeraye","year":"2015","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2018.07.004_bib40","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma","volume":"21","author":"Lacouture","year":"2016","journal-title":"The Oncologist"},{"issue":"10","key":"10.1016\/j.jaad.2018.07.004_bib41","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/cas.13022","article-title":"Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors","volume":"107","author":"Minami","year":"2016","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.004_bib42","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2013.01.023","article-title":"Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib","volume":"69","author":"Iarrobino","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2018.07.004_bib43","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamadermatol.2014.583","article-title":"Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage","volume":"150","author":"Zhu","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.004_bib44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.07.004_bib45","doi-asserted-by":"crossref","first-page":"5361569","DOI":"10.1155\/2016\/5361569","article-title":"Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature","volume":"2016","author":"Gencler","year":"2016","journal-title":"Dermatol Res Pract"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.004_bib46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"The Oncologist"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.004_bib47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.294.6.681","article-title":"Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years","volume":"294","author":"Christenson","year":"2005","journal-title":"JAMA"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218322278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218322278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:48:39Z","timestamp":1759272519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218322278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0190962218322278"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.004","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}